✦ LIBER ✦

Brief Report: A phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis

✍ Scribed by Sarah Krausz; Maria J. H. Boumans; Danielle M. Gerlag; Joelle Lufkin; Arno W. R. van Kuijk; Alian Bakker; Maarten de Boer; Beatrijs M. Lodde; Kris A. Reedquist; Eric W. Jacobson; Michael O'Meara; Paul P. Tak

Book ID: 112002643
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 361 KB
Volume: 64
Category: Article
ISSN: 0004-3591
DOI: 10.1002/art.34339

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Therapeutic benefit of blocking interleu

Therapeutic benefit of blocking interleukin-6 activity with an anti–interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: A randomized, double-blind, placebo-controlled, dose-escalation trial

✍ E. H. S. Choy; D. A. Isenberg; T. Garrood; S. Farrow; Y. Ioannou; H. Bird; N. Ch 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 176 KB 👁 1 views

LY2439821, a humanized anti–interleukin-

LY2439821, a humanized anti–interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study

✍ M. C. Genovese; F. Van den Bosch; S. A. Roberson; S. Bojin; I. M. Biagini; Peter 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 182 KB 👁 1 views

Long-term safety and maintenance of clin

Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double-blind, placebo-controlled trial

✍ George Nuki; Barry Bresnihan; Moraye B. Bear; Dorothy McCabe 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 93 KB 👁 3 views

The safety and efficacy of a JAK inhibit

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

✍ Joel M. Kremer; Bradley J. Bloom; Ferdinand C. Breedveld; John H. Coombs; Mark P 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 33 KB

The safety and efficacy of a JAK inhibit

✍ Joel M. Kremer; Bradley J. Bloom; Ferdinand C. Breedveld; John H. Coombs; Mark P 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 279 KB 👁 3 views

MLN3897 plus methotrexate in patients wi

MLN3897 plus methotrexate in patients with rheumatoid arthritis: Safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study

✍ Clarissa E. Vergunst; Danielle M. Gerlag; Lisa von Moltke; Michael Karol; Tim Wy 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 169 KB 👁 3 views

## Abstract ## Objective To assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of the CC chemokine receptor CCR1 antagonist MLN3897 in patients with rheumatoid arthritis (RA) receiving methotrexate (MTX). ## Methods In this phase IIa, proof‐of‐concept study, patients meeting the